New study tracks eczema drug safety in pregnant women
NCT ID NCT05721937
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 26 times
Summary
This study watches pregnant women with eczema who take the medicine CIBINQO (abrocitinib) and compares them to pregnant women with eczema who do not take it. The goal is to see if the medicine affects the baby's health at birth or during the first year of life. About 400 women will join, and their regular doctor visits are used to collect information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGNew York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.